HB4203 amends the Illinois Insurance Code to expand required health insurance coverage for cancer-related screenings and diagnostic testing. Beginning with policies issued, amended, delivered, or renewed on or after January 1, 2028, group accident and health insurance policies must cover annual Pap smears for all insureds without cost sharing, and must cover prostate cancer screening for certain insureds when recommended by a physician. The prostate screening mandate applies to asymptomatic individuals age 50 and over, African-American individuals age 40 and over, and individuals age 40 and over with a family history or genetic predisposition to prostate cancer.
The bill also adds a new ovarian cancer coverage requirement. For insureds at risk for ovarian cancer, insurers must cover an annual screening using medically viable methods for detection and diagnosis, including ultrasounds, MRIs, x-rays, CT scans, and CA-125 blood tests. The bill defines who is considered “at risk for ovarian cancer,” including people with certain family histories, BRCA1/BRCA2 mutations, or elevated CA-125 levels. It also clarifies that the ovarian cancer screening coverage may be subject to deductible, coinsurance, or other cost sharing, and it preserves an exception for specified disease or limited-benefit policies.
The bill’s impact is to broaden mandated preventive and diagnostic coverage under Illinois insurance law, increasing the scope of benefits that group health insurers must provide. It also updates statutory definitions for prostate cancer screening and ovarian cancer risk, and it expressly protects high-deductible health plans from losing HSA eligibility due to prostate cancer screening coverage. The effective date is delayed until 2028, giving insurers and employers time to adjust plan design and pricing.
Overall, the bill appears to have a public-health-oriented purpose and is framed as a coverage expansion for cancer detection and early diagnosis. Because no committee transcripts or votes were provided, there is no recorded legislative debate or vote history to indicate formal support or opposition. Based on the text alone, the measure is likely to be viewed favorably by patient advocates and health-care stakeholders focused on screening access, while insurers and employers may be concerned about added premium costs and administrative complexity.
Notable points of contention in the bill itself include the balance between expanded coverage and cost-sharing: Pap smears and certain prostate screenings must be covered without cost sharing, while ovarian cancer screening may still be subject to deductibles and coinsurance. Another potential issue is the targeted age and risk-based criteria for prostate screening, including the specific reference to African-American individuals age 40 and over, which may draw attention in policy discussions about equity, medical necessity, and actuarial impact.
HB4203 amends Section 356u of the Illinois Insurance Code to require specified group accident and health insurance policies to cover certain cancer screenings and diagnostic tests. It expands mandated benefits for Pap smears, prostate cancer screening, and ovarian cancer detection, while preserving exceptions for limited-benefit coverage and protecting high-deductible health plans from HSA disqualification. The bill changes insurer obligations for policies issued, amended, delivered, or renewed on or after January 1, 2028.
No committee transcripts or roll-call votes were provided, so there is no direct record of legislative debate or formal sentiment from lawmakers. The bill’s structure suggests a generally supportive public-health approach centered on early cancer detection and expanded insurance coverage. At the same time, the delayed effective date and the inclusion of some cost-sharing for ovarian cancer screening suggest an effort to balance access concerns with insurer and employer cost considerations.
The main policy tension is between broader mandated coverage and the cost implications for insurers, employers, and plan sponsors. Supporters would likely emphasize earlier detection, especially for higher-risk populations, while opponents may focus on premium increases, utilization, and administrative burden. A secondary point of contention is the differential treatment of screenings: Pap smears and certain prostate screenings are required without cost sharing, but ovarian cancer screening may still involve deductibles or coinsurance, which could be viewed as inconsistent by advocates. The bill’s race- and risk-based prostate screening criteria may also prompt discussion about fairness, medical standards, and implementation.